대마의 정신의학적 영향

키워드

참고문헌 (72)

1. "Canada becomes second nation in the world to legalize marijuana" (2018)[URL]
2. "Illinois joins 10 other U.S. states in legalizing recreational marijuana" (2019)[URL]
3. "난치병 환자, 의료용 대마 사용 가능해진다…국회 본회의 통과" (2018)[URL]
4. "국회 통과된 ‘대마’는 연초가 아닙니다" (2018)[URL]
5. "마약의 대명사 ‘대마’를 어찌 하오리까" (2019)[URL]
6. "Legalizing cannabis is the best way to protect kids from its harmful effects" (2018)[URL]
7. Wright S, "Recreational cannabinoid use : The hazards behind the"high"", J Fam Pract, 65, pp.770~779 (2016)
8. "日 대마 여중생 ‘발칵’...대마에 빠진 청소년 급증" (2019)[URL]
9. "Marijuana use and health effects"[URL]
10. "Drug scheduling"[URL]
11. American Psychiatric Association, "정신질환의 진단 및통계 편람" (2015), 학지사
12. El-Alfy AT, "Antidepressant-like effect of Delta(9)-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L", Pharmacol Biochem Behav, 95, pp.434~442 (2010)
13. Mechoulam R, "The endocannabinoid system and the brain", Annu Rev Psychol, 64, pp.21~47 (2013)
14. Boggs DL, "Clinical and preclinical evidence for functional interactions of cannabidiol and Delta(9)-tetrahydrocannabinol", Neuropsychopharmacol, 43, pp.142~154 (2018)
15. Rey AA, "Biphasic effects of cannabinoids in anxiety responses : CB1 and GABA(B)receptors in the balance of GABAergic and glutamatergic neurotransmission", Neuropsychopharmacol, 37, pp.2624~2634 (2012)
16. Giroud C, "E-cigarettes : A review of new trends in cannabis use", Int J Environ Res Public Health, 12, pp.9988~10008 (2015)
17. clinical psychiatry, "Kaplan & Sadock’s synopsis of psychiatry: behavioral sciences", pp.2015, Sadock BJ
18. Howlett AC, "International Union of Pharmacology. XXVII. Classification of cannabinoid receptors", Pharmacol Rev, 54, pp.161~202 (2002)
19. Fride E, "The endocannabinoid system during development : emphasis on perinatal events and delayed effects", Vitam Horm, 81, pp.139~158 (2009)
20. Nguyen VH, "Increased brain metabolism after acute administration of the synthetic cannabinoid HU210 : A small animal PET imaging study with F-18-FDG", Brain Res Bull, 87, pp.172~179 (2012)
21. Fu J, "A catalytically silent FAAH-1 variant drives anandamide transport in neurons", Nat Neurosci, 15, pp.64~69 (2011)
22. Gaetani S, "The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs", Int Rev Neurobiol, 85, pp.57~72 (2009)
23. Heishman SJ, "Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures", Pharmacol Biochem Behav, 37, pp.561~565 (1990)
24. D’Souza DC, "Blunted psychotomimetic and amnestic effects of Delta-9-tetrahydrocannabinol in frequent users of cannabis", Neuropsychopharmacol, 33, pp.2505~2516 (2008)
25. Green B, "Being stoned : a review of self-reported cannabis effects", Drug Alcohol Rev, 22, pp.453~460 (2003)
26. Lev-Ran S, "The association between cannabis use and depression : a systematic review and meta-analysis of longitudinal studies", Psychol Med, 44, pp.797~810 (2014)
27. D’Souza DC, "The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals : implications for psychosis", Neuropsychopharmacol, 29, pp.1558~1572 (2004)
28. Murray RM, "What can we learn about schizophrenia from studying the human model, drug-induced psychosis?", Am J Med Genet B, 162, pp.661~670 (2013)
29. D’Souza DC, "Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction", Biol Psychiatry, 57, pp.594~608 (2005)
30. Tarricone I, "The impact of substance use at psychosis onset on First Episode Psychosis course : Results from a 1 year follow-up study in Bologna", Schizophr Res, 153, pp.60~63 (2014)
31. Broyd SJ, "Acute and chronic effects of cannabinoids on human cognition-a systematic review", Biol Psychiatry, 79, pp.557~567 (2016)
32. Englund A, "Can we make cannabis safer?", Lancet Psychiat, 4, pp.643~648 (2017)
33. Asbridge M, "Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis", BMJ, pp.344~ (2012)
34. Dubois S, "The combined effects of alcohol and cannabis on driving : Impact on crash risk", Forensic Sci Int, 248, pp.94~100 (2015)
35. Ramaekers JG, "Dose related risk of motor vehicle crashes after cannabis use", Drug Alcohol Depen, 73, pp.109~119 (2004)
36. Imtiaz S, "The burden of disease attributable to cannabis use in Canada in 2012", Addiction, 111, pp.653~662 (2016)
37. Fischer B, "Crude estimates of cannabis-attributable mortality and morbidity in Canada-implications for public health focused intervention priorities", J Public Health(Oxf), 38, pp.183~188 (2016)
38. "The legalization of marijuana in Colorado: the impact volume 5" (2017)[URL]
39. Andreasson S, "Cannabis and schizophrenia. A longitudinal study of Swedish conscripts", Lancet, 2, pp.1483~1486 (1987)
40. Arseneault L, "Cannabis use in adolescence and risk for adult psychosis : longitudinal prospective study", Brit Med J, 325, pp.1212~1213 (2002)
41. Di Forti M, "Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users", Schizophr Bull, 40, pp.1509~1517 (2014)
42. Giordano GN, "The association between cannabis abuse and subsequent schizophrenia : a Swedish national corelative control study", Psychol Med, 45, pp.407~414 (2015)
43. Di Forti M, "High-potency cannabis and the risk of psychosis", Br J Psychiatry, 195, pp.488~491 (2009)
44. Fergusson DM, "Cannabis dependence and psychotic symptoms in young people", Psychol Med, 33, pp.15~21 (2003)
45. Galvez-Buccollini JA, "Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis", Schizophr Res, 139, pp.157~160 (2012)
46. Large M, "Cannabis use and earlier onset of psychosis", Arch Gen Psychiat, 68, pp.555~561 (2011)
47. Colizzi M, "Interaction between functional genetic variation of DRD2 and cannabis use on risk of psychosis", Schizophr Bull, 41, pp.1171~1182 (2015)
48. Caspi A, "Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene : longitudinal evidence of a gene X environment interaction", Biol Psychiatry, 57, pp.1117~1127 (2005)
49. van Winkel R, "Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up", Arch Gen Psychiat, 68, pp.148~157 (2011)
50. Solowij N, "The chronic effects of cannabis on memory in humans : a review", Curr Drug Abuse Rev, 1, pp.81~98 (2008)
51. Grant I, "Non-acute(residual)neurocognitive effects of cannabis use : A meta-analytic study", J Int Neuropsych Soc, 9, pp.679~689 (2003)
52. Schreiner AM, "Residual effects of cannabis use on neurocognitive performance after prolonged abstinence : a meta-analysis", Exp Clin Psychopharmacol, 20, pp.420~429 (2012)
53. Kalant OJ., "Report of the Indian Hemp Drugs Commission, 1893-94: a critical review", Int J Addict, 7, pp.77~96 (1972)
54. McGlothlin WH, "The marihuana problem : an overview", Am J Psychiatry, 125, pp.126~134 (1968)
55. Silins E, "Young adult sequelae of adolescent cannabis use : an integrative analysis", Lancet Psychiat, 1, pp.286~293 (2014)
56. Lane SD, "Performance of heavy marijuana-smoking adolescents on a laboratory measure of motivation", Addict Behav, 30, pp.815~828 (2005)
57. Lane SD, "Marijuana effects on sensitivity to reinforcement in humans", Neuropsychopharmacol, 26, pp.520~529 (2002)
58. Bloomfield MA, "Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms", Biol Psychiatry, 75, pp.470~478 (2014)
59. Volkow ND, "Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity", Proc Natl Acad Sci U S A, 111, pp.E3149~E3156 (2014)
60. Berridge KC, "What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?", Brain Res Brain Res Rev, 28, pp.309~369 (1998)
61. Morgan CJ, "Cerebrospinal fluid anandamide levels, cannabis use and psychotic-like symptoms", Br J Psychiatry, 202, pp.381~382 (2013)
62. Hirvonen J, "Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers", Mol Psychiatr, 17, pp.642~649 (2012)
63. Lopez-Quintero C, "Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: Results of the National Epidemiologic Survey on Alcohol and Related Conditions(NESARC)", Drug Alcohol Depen, 115, pp.120~130 (2011)
64. Blanco C, "Cannabis use and risk of psychiatric disorders prospective evidence from a US national longitudinal study", JAMA Psychiatry, 73, pp.388~395 (2016)
65. Budney AJ, "Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms", Drug Alcohol Depen, 86, pp.22~29 (2007)
66. Bonnet U, "The cannabis withdrawal syndrome : current insights", Subst Abuse Rehabil, 8, pp.9~37 (2017)
67. Bonn-Miller MO, "Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009", Psychol Serv, 9, pp.404~416 (2012)
68. Hazekamp A, "The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms", J Psychoactive Drugs, 45, pp.199~210 (2013)
69. Hazekamp A, "The prevalence and incidence of medicinal cannabis on prescription in The Netherlands", Eur J Clin Pharmacol, 69, pp.1575~1580 (2013)
70. Whiting PF, "Cannabinoids for Medical Use : A Systematic Review and Meta-analysis", JAMA, 313, pp.2456~2473 (2015)
71. Wong SS, "Medical Cannabinoids in Children and Adolescents: A Systematic Review", Pediatrics, pp.140~ (2017)
72. "FDA regulation of cannabis and cannabis-derived products: Questions and answers" (2019)[URL]

관련 논문AI추천